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The aimof this studywas to develop a scoring systemof the immunohistochemical (IHC) expression of luteinizing hormone/human
chorionic gonadotropin receptor (LHCG-R) in endometrial cancer (EC) patients. Nonconsecutive hysterectomy specimens
containing EC collected from April 2013 to October 2015 were selected. Hematoxylin-eosin stained sections from each case were
reviewed and representative sections from each tumorwere selected. IHC stainingwas performed for the detection of LHCG-R.The
percentage of stained cells and the staining intensitywere assessed in order to develop an immunohistochemical score.Moreover, we
examined the correlation of the score with grading and lymphovascular space invasion (LVSI). There was a statistically significant
positive correlation between grading and IHC scoring (𝑝 = 0.01) and a statistically significant positive correlation between LVSI
and IHC score (𝑝 < 0.01). In conclusion, we suggest that the immunohistochemical score presented here could be used as a marker
of bad prognosis of EC patients. Nevertheless, further studies are needed in order to validate it. The study was registered in the
Careggi Hospital public trials registry with the following number: 2013/0011391.
1. Introduction
Endometrial cancer (EC) is the most common gynecolog-
ical tumor. The incidence of endometrial cancer is going
to increase in the upcoming years. [1]. Most patients are
diagnosed at stage I and the 5-year overall survival ranges
from 74% to 91% [1]. Conversely, patients with metastatic
disease have a median survival of 7–12 months, in spite of
treatment [2].
In order to classify for improving the EC prognosis,
in 1983, Bokhman described two pathogenetic types of
endometrial carcinomas characterized by differentmetabolic,
morphological, and endocrine profiles: type 1 is more com-
mon (∼70–80%) and consists of endometrioid histology
and is low grade, diploid, hormone-receptor positive and
typical of obese women, and type 2 (20–30%) consists of
nonendometrioid histology, is high-grade, aneuploid, poorly
differentiated, hormone-receptor negative and typical of
nonobese women, and is associated with higher risk of
metastasis and poor prognosis. [3].
Nowadays, FIGO stage (International Federation of
Gynecology and Obstetrics), tumor histotype, depth of
myometrial invasion, presence of lymphovascular space inva-
sion (LVSI), and histological grading are used to tailor treat-
ment and to predict prognosis [1]. However, thismanagement
may lead to undertreatment [4].
Therefore, a variety of molecular biomarkers are under
investigation such as PI3 K/PTEN/AKT/mTOR pathway
alterations, CTNNB1, KRAS, and TP53mutations, andmeth-
ylation profile of MLH1 promoter [2] in order to improve
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the detection of women with increased risk of metastasis
and local recurrence and consequently tailor treatments
according to the patient’s molecular profile.
Themost comprehensivemolecular study of ECs has been
performed by The Cancer Genome Atlas (TCGA) network,
based on integrated genomic (whole genome sequencing,
exome sequencing, microsatellite instability (MSI) evalua-
tion, and copy number analysis), transcriptomic, and pro-
teomic analysis, suggesting a new classification in 4 different
classes depending on genomic features that may suggest
appropriate and personalized treatments [5].
The presence of luteinizing hormone/human chorionic
gonadotropin receptor (LHCG-R) in EC has already been
described in previous studies [6–10], suggesting a key role
in cell line proliferation an in invasion in vitro and in
preclinical models. Our group demonstrated that LHCG-
R acts through its receptor LH-R on the recruitment of
protein kinase A (PKA), which induced the activation of
beta 1 integrin receptors and the secretion of active matrix
metalloproteinase-2 ending in the triggering of cell invasive-
ness [6, 7]. Further we investigated the role of LHCG-R in
preclinical models showing that its overexpression increased
the ability of EC cells in local invasion and metastatic spread
in orthotopic xenograft mice [8]. Moreover, we reported that
a patient treated primarily with LHRH analogue showed no
clinical progression of the disease, giving new evidence of the
favourable impact of LHRH analogue treatment [9]. These
“in vivo” and preclinical data suggested a key role of LHGC-
R as bad prognostic marker; moreover they suggested that
LHCG-R could be used for the management of surgical and
postsurgical treatment and for surveillance.
In the literature, nowadays, there have been no prospec-
tive clinical studies that can confirm the role of LHCG-R in
patients with EC. However, studies of this type need to have a
simple, cost-effective and easily replicable system forDETER-
MINING LHCG-R in tumor tissue. Our previous studies
evaluated LHCG-R expression by RT-qPCR [7, 9]. Instead, in
our latest study, we also applied immunohistochemical (IHC)
evaluation [10].The IHC technique iswidely used in oncology
diagnostics, both for gynecological and nongynecological
specimens, and meets the above requirements of simplicity,
affordability, and repeatability [11, 12].
The aim of this study was to develop a scoring system
for the presence and the amount evaluation of LHCG-R by
IHC in EC.Moreover, we validated the clinical role of LHCG-
R score in EC cases. Indeed, we analyzed if the LHCG-R
expressionwas related to local invasion andmetastatic spread
associated with grading (G3) and to lymphovascular space
invasion (LVSI) [13].
2. Materials and Methods
2.1. Patients. Thirty (30) nonconsecutive EC hysterectomy
specimens collected from April 2013 to October 2015 at
Careggi University Hospital, Florence, Italy, were selected.
Informed consent was obtained from each patient.
Inclusion criteria were type 1 EC (endometrioid subtype),
grade 1 (G1) or 3 (G3), and availability of clinical data. The
following parameters were recorded for each case: age, BMI
(Body Mass Index), menopausal status, type of surgery, and
FIGO stages. The histological classification was performed
based on the World Health Organization (WHO) classi-
fication: grade 1 (G1) were endometrioid-type carcinomas
composed of glands with <5% solid nonsquamous growth,
while grade 3 (G3) had predominantly solid proliferation
(>50%). Grade 2 (G2) cancers were intentionally excluded to
identify two subgroups with different prognoses.The grading
evaluation increases when nuclear atypia (large, pleomorphic
nuclei, coarse chromatin, and large irregular nucleoli) was
>50% in the tumor (WHO). LVSIwas assessed for all patients.
All patients underwent surgery according to European
Society of Gynecological Oncology (ESGO) guidelines. Only
patients with presurgical stage ≥ IB underwent pelvic/para-
aortic lymphadenectomy. Patientswere staged retrospectively
according to the 2009 FIGO staging guidelines. Patients
defined as high-intermediate and high risk of recurrence
according to ESGO guidelines [14] underwent adjuvant
therapy.
Clinical, physiological, pathological, and follow-up fea-
tures of each patient are reported in Supplementary Table 1.
EC hysterectomy specimens were fixed in formalin and
embedded in paraffin (FFPE). Specific sections were per-
formed and analyzed by hematoxylin-eosin staining and
representative sections from each tumor were selected for
IHC analysis.
2.2. Immunohistochemistry. IHC staining was performed
on 3 𝜇m thick serial sections cut from formalin-fixed and
paraffin-embedded (FFPE) tissues.The antibody used for the
detection of LHCG-R was a rabbit, antihuman polyclonal
antibody (Novus Biologicals, Littleton, Colorado, USA) at
dilution 1 : 50, by overnight incubation at 4∘C. Antigen
retrieval was performed in a thermostatic bath (PT Link,
PretreatmentModule, Dako, Agilent, Santa Clara, California,
USA) at 97∘C with Citrate buffer 10mM pH 6 for 8 minutes.
For chromogenic detection, ultraView Universal Alkaline
Phosphatase Red Detection Kit (Ventana Medical Systems,
Tucson, Arizona, USA) was used. The sections were lightly
counterstained with Mayer’s hematoxylin solution. A nega-
tive control sample was performed by omitting the primary
antibody. Sections of corpus luteum were used as positive
control. The control sections were treated with the samples
in the same run.
2.3. Immunohistochemical (IHC) Scoring and Statistical Anal-
ysis. The IHC stained slides were microscopically analyzed
by two independent observers (E.P., F.C.). Specimens were
evaluated by focusing on the percentage of stained cells and
the intensity of cytoplasm stain. The percentage of stained
cells was graded as follows: 0 (0–24% of stained cells), 1
(25–49%), 2 (50–74%), and 3 (75–100%). The staining inten-
sity was scored as follows: 0 (absent), 1 (weak), 2 (strong),
and 3 (very strong). The sum of both parameters yielded the
immunohistochemical (IHC) score, which ranged from0 to 6
points. Tumors were divided into three categories depending
on the IHC score: Category I corresponded to IHC score
0–2, Category II to IHC score 3-4, and Category III to a IHC
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score 5-6. Examples of IHC score and categories are shown in
Supplementary Figure 1.
Chi-square statistics were used to test for correlations,
the evaluation of Chi-square statistical significance was per-
formed by 𝑝 value. Statistical significance was considered
achieved when the 𝑝 value was less than or equal to 0.05. All
statistical analyses were performed using Prism 7 for MAC.
3. Results and Discussion
3.1. Results. Thirty endometrioid EC tumors were evaluated:
15 (50%) G1 and 15 (50%) G3. The average age of the study
population was 66 years (range: 43–81 years). The mean
BMI was 31 (range: 19.5–40). Most of the patients were in
menopause (97%) and only one was in premenopause (3%);
the average menopausal age was 52.4 years (range: 46–59
years). Eleven patients underwent lymphadenectomy (11/30;
36.6%); among these patients, there was only one case with
node invasion (9%). Thirteen patients (13/30; 43.3%) under-
went adjuvant therapy: 2 patients had combined chemo- and
radiotherapy (15%) and 11 patients had only radiotherapy
(85%). Patients had an average follow-up of 30months (range:
18–49 months); during the study period one patient died of
disease (DOD) after 15 months of follow-up (FU) and one
patient experienced nodal recurrence at 22 months of FU
and she is still alive. Supplementary Table 1 showed patients’
clinical data and FU.
According to the IHC score, 11 patients (11/30; 36.6%)
were classified in IHC score category I, 9 patients (9/30; 30%)
in category II, and 10 patients (10/30; 33.3%) in category III.
The agreement between the two observers was 95%.
No significant distribution was observed among IHC
score categories and clinical, physiological, and pathological
features (BMI,menopause,myometrial invasion, FIGO stage,
presence of distant recurrence, FU, and survival) except for
grading and LVSI.
Regarding the correlation between IHC score category
and grading, within IHC score category I, 9 patients (9/11;
81.8%)wereG1 and 2 (2/11; 18.18%)wereG3; within IHC score
category II, 5 patients (5/9; 55.5%) were G1 and 4 (4/9; 44.4%)
were G3; finally, within IHC score category III there was only
one G1 patient (1/10; 10%) and 9 G3 patients (9/10; 90%).This
distribution showed a statistically significant positive relation
between grading and IHC scoring (𝑝 = 0.01) (Figure 1(a)).
Concerning the LVSI, 8 patients (8/30; 26.6%) presented
LVSI and 22 (22/30; 73.3%) were without LVSI. Within
the LVSI-positive patients, 2 (2/8; 25%) were in IHC score
category II and 6 (6/8; 75%) in IHC score category III.Within
LVSI-negative patients, there were 11 patients (11/22; 50%)
in IHC score category I, 7 (7/22; 31.8%) in category II, and
4 (4/22; 18.2%) in category III (Figure 1(b)). There was a
statistically significant positive relation between LVSI and
IHC score (𝑝 < 0.01). Notably, among the 8 LVSI-positive
patients, 7 (7/8; 87.5%) were G3 and 1 (1/8; 12.5%) was G1
(𝑝 = 0.035) (Figure 1(c)).
Finally, both the patients with nodal recurrence andDOD
were in IHC score category III.
4. Discussion
Endometrial cancer (EC) is the fourth most common cancer
overall and the most common malignancy of the female
reproductive tract and its incidence is increasing [15]. Several
epidemiological and histological factors such as increasing
age, depth of myometrial invasion, histological tumor type
and grade, presence of LVSI, and FIGO stage have been
reported to be correlated with a higher risk of recurrence and
nodal metastases in early-stage EC [14, 16–18]. Nevertheless,
the recurrence rate in these patients is widely variable,
ranging from 2% to 26% [16, 17, 19].
Therefore, not only is the identification of key fac-
tors/pathways responsible for the aggressiveness of EC, but
also additional prognostic tools are urgently needed to
improve the definition of a patient’s risk of recurrence [15].
Several biomarkers are under investigation for prognos-
tic, diagnostic, or therapeutic aims in EC, though no one of
them is currently used in clinical practice [14]. Numerous
studies were focused on the research of biomarkers for
discrimination of type I from type II mainly based onmRNA
expression in tissues [20–22] or on IHC procedure (i.e.,
L1CAM, PR, ER, STMN, and PTEN, USP14, Ki-67, even if the
latest is not a specific biomarker for EC, it is frequently and
routinely used for several kinds of tumors) [23–26] or in bio-
logical fluid [27]. The most used biomarker is circulating CA
125 but not only is the sensitivity unsatisfactory, especially in
early tumor stage, but also its specificity is low. Nevertheless
CA125 has no correlation with the prognosis of the patient
[28].
Recently, IHC scores based on the evaluation of ER and
HER-2 staining [29, 30] and PTEN were described [31].
Moreover, specific scores for prediction of recurrence have
been set based on gene signature and IHC [32].
Thepresence and role of the LH/hCG receptor (LHCG-R)
in EC have already been described in previous studies by our
group [6–10]. Indeed, our group has already demonstrated
that (i) LH/hCG induces an in vitro invasive phenotype,
through the activation of LHCG-R and hence of PKA [6];
(ii) LHCG-R mRNA is expressed in a small cohort primary
ECs [7]; (iii) primary treatment with Gn-RH analogues
(aimed to decrease the levels of serum LH) for six years in
a patient affected by EC with contraindications to surgery
was associated with no evidence of progression of the disease
throughout the study period [9]; and (iv) LHCG-R in a EC
preclinical mouse model behaves such as a prometastatic
molecular device [8]. Finally, we recently published a case of
a 51-year-old affected by G2 endometrioid EC, FIGO stage
IA. According to the conventional prognostic factors, the
patient was treated as a low-risk EC with surgery alone
and close follow-up. Surprisingly, six months after surgery
she developed an early vesicovaginal recurrence and, a few
months later, a subsequent involvement of the vaginal wall,
ileum, and omentum, despite the chemotherapy. We deter-
mined the LHCG-R expression in the surgical samples both
at mRNA level and at protein level; both evaluations turned
out to be highly expressed [9].The previously published data,
togetherwith those presented in thismanuscript,may suggest
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Figure 1: Correlation between LHCG-R IHC score categories and pathological features. (a) LHCG-R IHC score categories and grading (G1
and G3). (b) LHCG-R IHC score categories and LVSI. LVSI+: positive LVSI. LVSI−: negative LVSI. (c) Correlation between LVSI (LVSI+ and
LVSI−) and grading (G1 and G3).
a relation between LHCG-R expression and poor prognosis
in EC.
In this manuscript, we focused on the evaluation of
prognostic use of LHCG-R in a selected subgroup of sample
characterized by type I EC in order to investigate receptor
level and unexpected recurrences.
The presence of LHCG-Rwas investigated by IHC andwe
set a score that considers the amount (intensity) and spread
(percentage of stained cells) of LHCG-R positive cells. Even if
a small cohortwas analyzed, we showed a correlation between
LHCG-R IHC score and LVSI and Grading. G3 patients have
a significantly higher score than G1 patients; similarly, LVSI-
positive patients have a significantly higher score than LVSI-
negative patients, suggesting a key role played by this receptor
in EC cancer development in terms of invasiveness and bad
prognosis. Moreover, the evaluation of LHCG-R expression
can be used for diagnostic purpose, but also for treatment
setting. In a previous study [9], we noticed that the treatment
in a patient presenting high level of LHCG-R and the use of
LHGC-R analogues allowed maintaining the tumor without
increasing of growth and invasion.
All these data point out the fact that the evaluation
of LHGC-R could be adopted as a new biomarker for
implementing decision-making process of the pathologist
and overcoming the pitfalls harbored in the grading and LVSI
assessment for some critical samples. Therefore, the LHCG-
R IHC score might represent a new tool to better identify EC
patients with negative prognostic factors.
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Supplementary Materials
Supplementary 1. Supplemental Table 1: clinical physiological
and pathological characteristics and follow-up of patients.
y: years; BMI: body mass index; ECa: endometrioid EC; m:
months; NED: no evidence of disease; DOD: died of disease;
FU: follow-up.
Supplementary 2. Supplemental Figure 1: LHCG-R IHC
score evaluation in endometrial cancer: two example cases.
Panels A and B: hematoxylin-eosin staining; panels C and D:
corresponding immunohistochemistry (IHC) for LH/hCG-
R. Panel A (patient 1): endometrioid adenocarcinoma grade
1 composed of atypical glands (arrow head) with nuclear
atypia (magnificationX20). Panel B (patient 2): endometrioid
adenocarcinoma with more than 50% of a nonsquamous or
nonmorular solid growth pattern (star) (magnification, X20).
Panel C (patient 1): LHCG-R IHC with very strong intensity
at cytoplasmatic level (score 3) and 80 % of cells stained
(score 3), LHCG-R IHC score category III (magnification
X20). Panel D (patient 2): some areas with strong intensity
and others with weak or absent (arrow) stained cells (score 2)
and about 60 % of stained cells (score 2), LHCG-R IHC score
category II (magnification X20).
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